Fixed-dose combination
Benzoyl peroxide and Clindamycin is a fixed-dose combination medicine indicated for the topical treatment of acne vulgaris in patients 12 years of age and older, among other approved uses. MedsAcross supplies Benzoyl peroxide and Clindamycin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/3.75% is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. Clindamycin Phosphate and Benzoyl Peroxide Gel is a combination of clindamycin phosphate (a lincosamide antibacterial) and benzoyl peroxide indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
Source: US FDA prescribing information
Clindamycin: Clindamycin is a lincosamide antibacterial. Benzoyl Peroxide: Benzoyl peroxide is an oxidizing agent with bactericidal and keratolytic effects but the precise mechanism of action is unknown.
Source: US FDA prescribing information
Before applying clindamycin phosphate and benzoyl peroxide gel, wash the face gently with a mild soap, rinse with warm water, and pat the skin dry. Apply a pea-sized amount of clindamycin phosphate and benzoyl peroxide gel to the face once daily. Avoid the eyes, mouth, mucous membranes, or areas of broken skin. Use of clindamycin phosphate and benzoyl peroxide gel beyond 12 weeks has not been evaluated. Clindamycin Phosphate and Benzoyl Peroxide Gel is not for oral, ophthalmic, or intravaginal use. • Apply a pea-sized amount of clindamycin phosphate and benzoyl peroxide gel to the face once daily. • Not for oral, ophthalmic, or intravaginal use.
Source: US FDA prescribing information
Clindamycin Phosphate and Benzoyl Peroxide Gel is contraindicated in: • Patients who have demonstrated hypersensitivity (e.g., anaphylaxis) to clindamycin, benzoyl peroxide, any components of the formulation, or lincomycin. • Patients with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis.
Source: US FDA prescribing information
• Colitis: Clindamycin can cause severe colitis, which may result in death. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of clindamycin. Clindamycin Phosphate and Benzoyl Peroxide Gel should be discontinued if significant diarrhea occurs. • Ultraviolet Light and Environmental Exposure: Minimize sun exposure following drug application.
Source: US FDA prescribing information
The following adverse reaction is described in more detail in the Warnings and Precautions section of the label: • Colitis. The most common adverse reactions are: burning sensation (0.4%), contact dermatitis (0.4%), pruritus (0.4%), and rash (0.4%).
Source: US FDA prescribing information
Avoid using clindamycin phosphate and benzoyl peroxide gel in combination with topical or oral erythromycin-containing products because of its clindamycin component.
Source: US FDA prescribing information
Store at room temperature up to 25°C (77°F). Do not freeze.” Storage and Handling • PHARMACIST: Prior to Dispensing: Store in a refrigerator, 2° to 8°C (36° to 46°F). • PATIENT: After Dispensing: Discard unused portion 8 weeks after date of dispensing. Store at room temperature at or below 25°C (77°F). • Protect from freezing. • Store pump upright. • Keep out of the reach of children • Keep container tightly closed.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
6 presentations of Benzoyl peroxide and Clindamycin, sorted by availability.
| Medicine | Active ingredient | Manufacturer | Register | Availability |
|---|---|---|---|---|
| Benzoyl peroxide and Clindamycin 50 mg/10 mg per g gelTopical Cold chainGeneric name | Benzoyl peroxide and Clindamycin | — | US FDA | Available on request |
| Benzoyl peroxide and Clindamycin 25 mg/10 mg per g gelTopical Cold chainGeneric name | Benzoyl peroxide and Clindamycin | — | US FDA | Available on request |
| Benzoyl peroxide and Clindamycin 37.5 mg/10 mg per g gelTopical Cold chainGeneric name | Benzoyl peroxide and Clindamycin | — | US FDA | Available on request |
| Onexton 37.5 mg/10 mg per g gelTopical Cold chain | Benzoyl peroxide and Clindamycin | Bausch Health | US FDA | Available on request |
| Acanya 25 mg/10 mg per g gelTopical Cold chain | Benzoyl peroxide and Clindamycin | Bausch Health | US FDA | Available on request |
| Neuac 50 mg/10 mg per g gelTopical Cold chain | Benzoyl peroxide and Clindamycin | Medimetriks Pharmaceuticals | US FDA | Available on request |
3 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 21 December 2000 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 6 presentations of Benzoyl peroxide and Clindamycin and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 3 brand names for Benzoyl peroxide and Clindamycin, including Acanya, Neuac, Onexton.
Yes. The US FDA first approved Benzoyl peroxide and Clindamycin on 21 December 2000, according to Drugs@FDA.
At least one listed presentation of Benzoyl peroxide and Clindamycin must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.